MX2016009047A - Anticuerpos dirigidos contra interleucina-33 (il-33). - Google Patents

Anticuerpos dirigidos contra interleucina-33 (il-33).

Info

Publication number
MX2016009047A
MX2016009047A MX2016009047A MX2016009047A MX2016009047A MX 2016009047 A MX2016009047 A MX 2016009047A MX 2016009047 A MX2016009047 A MX 2016009047A MX 2016009047 A MX2016009047 A MX 2016009047A MX 2016009047 A MX2016009047 A MX 2016009047A
Authority
MX
Mexico
Prior art keywords
chain polypeptide
directed against
antibodies directed
against interleukin
binding agent
Prior art date
Application number
MX2016009047A
Other languages
English (en)
Inventor
A Horlick Robert
J King David
John Mcknight Andrew
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of MX2016009047A publication Critical patent/MX2016009047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a un polipéptido de cadena pesada de inmunoglobulina aislado y un polipéptido de cadena ligera de inmunoglobulina aislado que se enlazan a interleucina-33 (IL-33). La invención proporciona un agente de enlace a IL-33 que comprende el polipéptido de cadena pesada de inmunoglobulina y el polipéptido de cadena ligera de inmunoglobulina anteriormente mencionados. La invención también proporciona vectores, composiciones, y métodos relacionados al uso del agente de enlace a IL-33 para tratar un trastorno en un mamífero que responde a inhibición de IL 33.
MX2016009047A 2014-01-10 2015-01-09 Anticuerpos dirigidos contra interleucina-33 (il-33). MX2016009047A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925946P 2014-01-10 2014-01-10
PCT/US2015/010785 WO2015106080A2 (en) 2014-01-10 2015-01-09 Antibodies directed against interleukin-33 (il-33)

Publications (1)

Publication Number Publication Date
MX2016009047A true MX2016009047A (es) 2017-04-13

Family

ID=53524474

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009047A MX2016009047A (es) 2014-01-10 2015-01-09 Anticuerpos dirigidos contra interleucina-33 (il-33).
MX2020001272A MX2020001272A (es) 2014-01-10 2016-07-08 Anticuerpos dirigidos contra interleucina-33 (il-33).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001272A MX2020001272A (es) 2014-01-10 2016-07-08 Anticuerpos dirigidos contra interleucina-33 (il-33).

Country Status (14)

Country Link
US (3) US10059764B2 (es)
EP (1) EP3092253B1 (es)
JP (2) JP2017503506A (es)
KR (1) KR102446386B1 (es)
CN (1) CN106103480B (es)
AU (1) AU2015204674B2 (es)
BR (1) BR112016016020B1 (es)
CA (1) CA2936366A1 (es)
ES (1) ES2866935T3 (es)
MX (2) MX2016009047A (es)
NZ (1) NZ722445A (es)
RU (2) RU2019118984A (es)
SG (2) SG10201805934RA (es)
WO (1) WO2015106080A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004697A2 (en) 2006-04-07 2008-12-24 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
BR112016013347B1 (pt) 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
JP2017503506A (ja) 2014-01-10 2017-02-02 アナプティスバイオ インコーポレイティッド インターロイキン−３３（ｉｌ−３３）に対する抗体
CN107109494B (zh) 2014-11-10 2023-10-27 豪夫迈·罗氏有限公司 Il-33介导型疾病的治疗方法和诊断方法
KR20170080604A (ko) 2014-11-10 2017-07-10 제넨테크, 인크. 항-인터류킨-33 항체 및 그것의 용도
SG11201805900YA (en) * 2016-01-14 2018-08-30 Anaptysbio Inc Inhibition of allergic reaction using an il-33 inhibitor
CN109415436A (zh) * 2016-04-27 2019-03-01 辉瑞公司 抗il-33抗体及其组合物、方法及用途
MX2019000727A (es) 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TW202332696A (zh) 2016-12-01 2023-08-16 美商再生元醫藥公司 治療發炎症狀的方法
AU2017381585A1 (en) 2016-12-19 2019-07-18 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
KR102362006B1 (ko) 2017-02-10 2022-02-14 제넨테크, 인크. 항-트립타제 항체, 이의 조성물, 및 그의 용도
WO2018190990A1 (en) 2017-04-13 2018-10-18 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
KR20200044812A (ko) 2017-08-31 2020-04-29 미쓰비시 타나베 파마 코퍼레이션 Il-33 안타고니스트를 포함하는 자궁내막증 치료제
TW201922280A (zh) 2017-10-09 2019-06-16 美商安納普提斯生物公司 用於異位性皮膚炎之抗-il-33 療法
WO2019157358A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019183639A1 (en) * 2018-03-23 2019-09-26 Anaptysbio, Inc. Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantification of IL-33
TW202021983A (zh) 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US20220363748A1 (en) 2019-11-04 2022-11-17 Medimmune Limited Anti il-33 therapeutic agent for treating renal disorders
WO2021089563A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Methods of using il-33 antagonists
JPWO2021157619A1 (es) 2020-02-05 2021-08-12
CN115315527A (zh) 2020-03-13 2022-11-08 免疫医疗有限公司 用于治疗il33中存在风险等位基因的受试者的治疗方法
CN115605507A (zh) 2020-03-13 2023-01-13 基因泰克公司（Us） 抗白介素-33抗体及其用途
JP2023521061A (ja) 2020-04-06 2023-05-23 メドイミューン・リミテッド Ｉｌ－３３軸結合アンタゴニストによる急性呼吸窮迫症候群の治療
CA3181765A1 (en) 2020-05-11 2021-11-18 Medimmune Limited Formulations of anti-il-33 antibodies
US20210380721A1 (en) * 2020-06-01 2021-12-09 University Of Kentucky Research Foundation Compounds and methods for use in connection with opioid use disorders
EP4178565A2 (en) * 2020-07-07 2023-05-17 The General Hospital Corporation Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation
KR20220022226A (ko) * 2020-08-18 2022-02-25 성균관대학교산학협력단 Il-33 항체 또는 이의 항원 결합 단편
CN114249825A (zh) * 2020-09-25 2022-03-29 三生国健药业（上海）股份有限公司 结合人il-33的抗体、其制备方法和用途
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038185A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Method of selecting patients for treatment with an il-33 axis antagonist

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
AU650085B2 (en) 1990-11-13 1994-06-09 Immunex Corporation Bifunctional selectable fusion genes
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
KR20140097582A (ko) * 2005-07-18 2014-08-06 암젠 인크 인간 항-ｂ7ｒｐ1 중화 항체
WO2007130627A2 (en) 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
CA2914170C (en) 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
CA2678451A1 (en) 2007-02-20 2008-08-28 Robert A. Horlick Somatic hypermutation systems
US8119771B2 (en) 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
AU2008254704A1 (en) * 2007-05-18 2008-11-27 Medimmune, Llc IL-33 in inflammatory disease
KR20110025859A (ko) * 2008-06-30 2011-03-11 모르포테크, 인크. 항-ｇｄ２ 항체 및 이와 관련된 방법 및 용도
BRPI1007371A2 (pt) 2009-01-29 2018-03-27 Abbott Lab proteínas de ligação a il-1
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
HUE027077T2 (en) 2009-10-15 2016-08-29 Avaxia Biologics Inc Antibody therapy with local activity in the digestive system
TWI615405B (zh) 2010-05-14 2018-02-21 艾伯維有限公司 Ｉｌ-１結合蛋白
KR20140005864A (ko) * 2010-08-16 2014-01-15 암젠 인코퍼레이티드 미오스타틴에 결합하는 항체, 조성물 및 방법
EP2635307B1 (en) 2010-11-01 2020-07-29 Melinta Subsidiary Corp. Pharmaceutical compositions
US20120156194A1 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
CA2853258A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
BR112014009962A2 (pt) * 2011-10-27 2019-09-24 Nkt Therapeutics Inc anticorpos humanizados para inkt
CA2865154A1 (en) 2012-02-24 2013-08-29 Children's Hospital Medical Center Esophageal microrna expression profiles in eosinophilic esophagitis
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
WO2014022294A1 (en) 2012-07-31 2014-02-06 Novartis Ag Treating inflammation using serelaxin
US20150250808A1 (en) 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
AU2013357427B2 (en) 2012-12-10 2017-08-31 Universiteit Gent Novel Interleukin-33 inhibitors
KR101780575B1 (ko) 2013-02-14 2017-09-21 건국대학교 산학협력단 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
ME03348B (me) 2013-08-12 2019-10-20 Astrazeneca Ab Metode za smanjenje stopa pogoršavanja astme korišćenjem benralizumaba
KR101567758B1 (ko) 2013-10-17 2015-11-11 인하대학교 산학협력단 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물
SG11201603127WA (en) 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
BR112016013347B1 (pt) 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
JP2017503506A (ja) 2014-01-10 2017-02-02 アナプティスバイオ インコーポレイティッド インターロイキン−３３（ｉｌ−３３）に対する抗体
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
CA2946511C (en) 2014-04-21 2023-08-22 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
CN107109494B (zh) 2014-11-10 2023-10-27 豪夫迈·罗氏有限公司 Il-33介导型疾病的治疗方法和诊断方法
KR20170080604A (ko) 2014-11-10 2017-07-10 제넨테크, 인크. 항-인터류킨-33 항체 및 그것의 용도
US20180036404A1 (en) 2015-03-02 2018-02-08 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
MA50638A (fr) 2015-10-06 2020-08-05 Regeneron Pharma Biomarqueurs associés aux maladies médiées par l'interleukine-33 (il-33) et leurs utilisations
SG11201805900YA (en) 2016-01-14 2018-08-30 Anaptysbio Inc Inhibition of allergic reaction using an il-33 inhibitor

Also Published As

Publication number Publication date
JP2020018309A (ja) 2020-02-06
WO2015106080A3 (en) 2015-09-11
RU2019118984A (ru) 2019-08-06
CN106103480A (zh) 2016-11-09
BR112016016020A2 (pt) 2018-05-22
KR102446386B1 (ko) 2022-09-22
US20210040198A1 (en) 2021-02-11
KR20160132006A (ko) 2016-11-16
MX2020001272A (es) 2020-07-20
JP6882702B2 (ja) 2021-06-02
US10059764B2 (en) 2018-08-28
EP3092253A2 (en) 2016-11-16
US20160333090A1 (en) 2016-11-17
AU2015204674A1 (en) 2016-08-25
AU2015204674B2 (en) 2020-09-03
CA2936366A1 (en) 2015-07-16
RU2693084C2 (ru) 2019-07-01
EP3092253B1 (en) 2021-03-17
WO2015106080A2 (en) 2015-07-16
US10836820B2 (en) 2020-11-17
EP3092253A4 (en) 2017-11-29
BR112016016020B1 (pt) 2024-02-27
SG11201605580RA (en) 2016-10-28
RU2016132757A3 (es) 2018-07-16
US20180346562A1 (en) 2018-12-06
NZ722445A (en) 2022-07-01
CN106103480B (zh) 2021-10-22
RU2016132757A (ru) 2018-02-16
JP2017503506A (ja) 2017-02-02
ES2866935T3 (es) 2021-10-20
SG10201805934RA (en) 2018-08-30

Similar Documents

Publication Publication Date Title
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
MX2017012429A (es) Anticuerpos dirigidos contra la inmunoglobulina de celulas t y la proteina mucina 3 (tim-3).
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
NZ738008A (en) Tigit-binding agents and uses thereof
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2015015037A (es) Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
NZ766356A (en) Anti-pd-1 antibodies
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
NZ724815A (en) Humanized antibodies that bind lgr5
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
WO2015116569A3 (en) Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2019002349A (es) Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control.
EA202092572A1 (ru) Композиции и способы обнаружения и лечения рака пищевода

Legal Events

Date Code Title Description
FG Grant or registration